SNY acquires PRVB for $25.00 cash—a 273%(!) premium to Friday’s closing price: https://finance.yahoo.com/news/press-release-sanofi-acquire-provention-060000049.html The nominal deal value is $2.9B. SNY and PRVB already had a US co-marketing deal for Tzield, PRVB’s novel drug to delay the onset of T1D (#msg-170131014).